7,683.00

+2.50

+0.03%

52,767.00

-65.00

-0.12%

29,569.25

+30.50

+0.10%

Russell 2000 Futures

2,961.70

-1.90

-0.06%

15.87

+0.15

+0.95%

4,444.40

+5.40

+0.12%

79,640.50

+907.62

+1.15%

Crude Oil Oct 26

94.55

+1.52

+1.63%

NasdaqCM - Delayed Quote USD

Tenaya Therapeutics, Inc. (TNYA)

Get top stock picks

0.6634 -0.0198 (-2.90%)

At close: September 8 at 4:00:00 PM EDT

0.6899 +0.0265 (+3.99%)

Pre-Market: 4:55:09 AM EDT

Get top stock picks

Loading Chart for TNYA

Chart Range Bar

Interval:

In partnership with ChartIQ

Tenaya Therapeutics to Participate in Upcoming September Investor Conferences

Tenaya Therapeutics to Participate in Upcoming September Investor Conferences

Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301

Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301

Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms

Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC

Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC

Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026

Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026

Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026

Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026

Tenaya Therapeutics, Inc. (TNYA) Reports Q1 Loss, Misses Revenue Estimates

Tenaya Therapeutics, Inc. (TNYA) Reports Q1 Loss, Misses Revenue Estimates

Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026

Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026

William Blair Analysts Confident on Tenaya Therapeutics (TNYA) Product Pipeline

William Blair Analysts Confident on Tenaya Therapeutics (TNYA) Product Pipeline

SGMO

ATYR

ALXO

GNPX

LIMN

PSTV

VIVS

SER

GUTS

ANL

Mobilize your Website

View Site in Mobile | Classic

Share by: